Introduction
Cizzle Biotechnology Holdings plc has entered a strategic partnership with BBI Solutions to supply the first order of proprietary monoclonal antibodies for early-stage lung cancer detection. This collaboration is a significant step in Cizzle’s mission to commercialize its biomarker test.
Key Highlights
- Partnership: BBI Solutions will manufacture CIZ1B monoclonal antibodies.
- Certified Production: Manufactured in ISO 13485-certified facilities.
- Initial Supply: First batch supports up to 5000 blood tests.
- Clinical Evaluation: Facilitates evaluations with a major US cancer center.
Commercialization Strategy
- US CLIA Accreditation: Aim for registration in September 2024.
- Product Launch: Planned for April 2025.
- POC Development: Developing a point-of-care test.
- Expanded Research: Continued R&D at the University of York.
Further Information
Cizzle is committed to bringing its CIZ1B test to market quickly, aiming to save lives through early detection. The new antibodies will be used in clinical evaluations, developing point-of-care tests, and researching the test’s utility for other cancers.
Quotes
Allan Syms, Executive Chairman of Cizzle Biotechnology, highlights the progress in making the CIZ1B test available for early lung cancer detection.
Mario Gualano, CEO of BBI Solutions, emphasizes their role in ensuring the highest quality standards for the antibodies.
About Cizzle Biotechnology
Cizzle Biotechnology is a UK-based diagnostics company focusing on developing a cost-effective biomarker test for early-stage lung cancer, based on detecting the CIZ1B variant.
About Cizzle Bio, Inc.
Cizzle Bio Inc., based in Texas, USA, is dedicated to improving cancer patient survival through early detection using the CIZ1B biomarker test, led by entrepreneur Bill Behnke.
About BBI Solutions
BBI Solutions is a leading producer of immunodiagnostic reagents, specializing in high-quality raw materials and custom development solutions with ISO 13485 certification.
Conclusion
The partnership with BBI Solutions advances Cizzle Bio’s mission to bring its innovative lung cancer detection test to market, potentially saving thousands of lives through early diagnosis.
For more information, please visit BBI Solutions.